Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study.
Muñoz-Valle JF, Sánchez-Zuno GA, Matuz-Flores MG, Hernández-Ramírez CO, Díaz-Pérez SA, Baños-Hernández CJ, Turrubiates-Hernández FJ, Vega-Magaña AN, Hernández-Bello J. Muñoz-Valle JF, et al. Among authors: diaz perez sa. Vaccines (Basel). 2022 Mar 5;10(3):400. doi: 10.3390/vaccines10030400. Vaccines (Basel). 2022. PMID: 35335032 Free PMC article.
Aberrant B-cell activation and B-cell subpopulations in rheumatoid arthritis: analysis by clinical activity, autoantibody seropositivity, and treatment.
Morales-Núñez JJ, Muñoz-Valle JF, García-Chagollán M, Cerpa-Cruz S, Martínez-Bonilla GE, Medina-Rosales VM, Díaz-Pérez SA, Nicoletti F, Hernández-Bello J. Morales-Núñez JJ, et al. Among authors: diaz perez sa. Clin Exp Immunol. 2023 Dec 13;214(3):314-327. doi: 10.1093/cei/uxad076. Clin Exp Immunol. 2023. PMID: 37464892
Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies.
Morales-Núñez JJ, Muñoz-Valle JF, Machado-Sulbarán AC, Díaz-Pérez SA, Torres-Hernández PC, Panduro-Espinoza BV, Gallegos-Díaz de Leon JA, Munguía-Ramirez CD, Hernández-Bello J. Morales-Núñez JJ, et al. Among authors: diaz perez sa. Immunol Lett. 2022 Dec;251-252:20-28. doi: 10.1016/j.imlet.2022.10.002. Epub 2022 Oct 21. Immunol Lett. 2022. PMID: 36279685 Free PMC article.
BNT162b2 Vaccination after SARS-CoV-2 Infection Changes the Dynamics of Total and Neutralizing Antibodies against SARS-CoV-2: A 6-Month Prospective Cohort Study.
Hernández-Bello J, Sierra-García-de-Quevedo JJ, Morales-Núñez JJ, Santoscoy-Ascencio G, Díaz-Pérez SA, Gutiérrez-Brito JA, Muñoz-Valle JF. Hernández-Bello J, et al. Among authors: diaz perez sa. Vaccines (Basel). 2023 Jun 20;11(6):1127. doi: 10.3390/vaccines11061127. Vaccines (Basel). 2023. PMID: 37376516 Free PMC article.
Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19 - A Prospective Cohort Study.
Morales-Núñez JJ, García-Chagollán M, Muñoz-Valle JF, Díaz-Pérez SA, Torres-Hernández PC, Rodríguez-Reyes SC, Santoscoy-Ascencio G, Sierra García de Quevedo JJ, Hernández-Bello J. Morales-Núñez JJ, et al. Among authors: diaz perez sa. J Inflamm Res. 2022 Aug 4;15:4449-4466. doi: 10.2147/JIR.S374304. eCollection 2022. J Inflamm Res. 2022. PMID: 35958186 Free PMC article.
Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2.
Hernández-Bello J, Morales-Núñez JJ, Machado-Sulbarán AC, Díaz-Pérez SA, Torres-Hernández PC, Balcázar-Félix P, Gutiérrez-Brito JA, Lomelí-Nieto JA, Muñoz-Valle JF. Hernández-Bello J, et al. Among authors: diaz perez sa. Vaccines (Basel). 2021 Sep 20;9(9):1047. doi: 10.3390/vaccines9091047. Vaccines (Basel). 2021. PMID: 34579284 Free PMC article.